{
    "Trade/Device Name(s)": [
        "EliA M2 Immunoassay"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K181556",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141375"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DBM"
    ],
    "Summary Letter Date": "July 13, 2018",
    "Summary Letter Received Date": "June 13, 2018",
    "Submission Date": "June 12, 2018",
    "Regulation Number(s)": [
        "21 CFR 866.5090"
    ],
    "Regulation Name(s)": [
        "Antimitochondrial antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgG antibodies specific for M2 protein"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Li-heparin, EDTA)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 2500",
        "Phadia 5000"
    ],
    "Method(s)/Technology(ies)": [
        "Semi-quantitative immunoassay",
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunofluorescence measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for EliA M2 Immunoassay for detection of anti-M2 IgG antibodies using semi-quantitative immunoassay on Phadia 2500/5000 automated platforms",
    "Indications for Use Summary": "Intended for in vitro semi-quantitative measurement of IgG antibodies to M2 in human serum and plasma to aid in clinical diagnosis of primary biliary cirrhosis, used with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}